Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study
BioDrugs · 2024
DOI: 10.1007/s40259-024-00666-1 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift BioDrugs, 2024. Verfasst von Helen W Wong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Oakland, Oakland, CA, USA. Hauptthemen laut MEDLINE: Rituximab, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Oakland, Oakland, CA, USA.
- Kaiser Permanente San Diego, San Diego, CA, USA.
- Kaiser Permanente Drug Use Management-Clinic Administered and Specialty Medications, Oakland, CA, USA.
- Kaiser Permanente Pharmacy Outcomes Research Group, Downey, CA, USA.
- Kaiser Permanente South San Francisco, South San Francisco, CA, USA.
- Kaiser Permanente Drug Intelligence and Strategy, Oakland, CA, USA.
ORCID-Profile: Lisa Law
Zitieren
APA
Wong, H. W., Nguyen, V. H., Mok, T. Y., Niu, F., Cushing, M., Lam, M., Ho, S. L., Law, L., Aziz, A. R., & Hui, R. L. (2024). Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs. https://doi.org/10.1007/s40259-024-00666-1
Vancouver
Wong HW, Nguyen VH, Mok TY, Niu F, Cushing M, Lam M, et al. Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs. 2024. doi:10.1007/s40259-024-00666-1
BibTeX
@article{Wong2024,
author = {Wong, Helen W and Nguyen, Vivian H and Mok, Timothy Y and Niu, Fang and Cushing, Merta and Lam, Michael and Ho, Stephanie L and Law, Lisa and Aziz, Ashraf R and Hui, Rita L},
title = {Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study},
journal = {BioDrugs},
year = {2024},
doi = {10.1007/s40259-024-00666-1}
}
EUVIMED